Expanding Global Adoption With over 250 hospitals using the ER-REBOA™ Catheter across the US, Europe, and Canada, Prytime Medical demonstrates strong international market penetration. There is an opportunity to further expand into additional regions and healthcare systems seeking advanced hemorrhage control solutions.

Innovative Product Portfolio The launch of new devices like the pREBOA-PRO and ER-REBOA™ PLUS indicates ongoing product innovation tailored to meet clinical needs for different emergency scenarios. This focus on expanding minimally invasive solutions creates potential for sales of upgraded and complementary devices.

Strategic Leadership Growth Recent appointments of industry leaders such as a new CEO, Chief Commercialization Officer, and Clinical Advisory Board members reflect a strategic push toward market expansion and commercialization. Building relationships with key clinical champions can accelerate adoption across trauma centers and emergency departments.

Military-to-Civilian Innovation Prytime’s roots in military trauma sciences and the transfer of combat-proven technology into civilian healthcare position the company as a leader in battlefield-influenced hemorrhage control. Partnering with military and trauma centers can open avenues for advanced training and product placement.

Market Growth Opportunities The initial success in trauma and emerging interest in adjacent markets such as cardiac arrest, postpartum hemorrhage, and pre-hospital care suggest significant growth potential. Strategies focused on these segments can unlock new revenue streams and reinforce Prytime’s position as an innovator.